1H17 results in line; sales growth remained weak Hong Kong NDR takeaways Buy: 2Q17 beat on margin and construction business A mixed picture of future growth and near term margin pressure; Hold Revitalizing in 2H 2017 In-line 1H 2017 Results. Tissue paper remains a growth driver Insulin slowed down, 6-APA positives reflected. Maintain HOLD. Earnings improved but potential yet to be released: Maintain BUY Virscend Education Interim Results Concerns about Q2 results put to rest. Optics business development will trigger a further re-rating.